SUBSEQUENT EVENTS |
9 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2024 | |||||||||||||||||||||||||
Subsequent Events [Abstract] | |||||||||||||||||||||||||
SUBSEQUENT EVENTS |
15. SUBSEQUENT EVENTS
The Company has evaluated subsequent events through November 5, 2024, the date these financial statements are available to be issued. The Company believes there were no material events or transactions discovered during this evaluation that requires recognition or disclosure in the financial statements other than the items discussed below.
Series C Preferred Shares Redeemed in Exchange for Common Shares
On December 29, 2023, the Company issued 10% annual dividend. Series C Preferred Shares to an institutional investor pursuant to a securities purchase agreement and certificate of designation previously filed. The Series C Preferred Shares carried a
Subsequent to September 30, 2024, the Company redeemed Series C Preferred Shares in exchange for common shares to fully redeem the Series C Preferred Shares that were outstanding. On October 14, 2024, the Company redeemed Series C Preferred Shares in exchange for common shares to fully repay the amount accrued for preferred dividends. The transaction was done at the Nasdaq at-the-market price. No broker was involved in the transaction and no fees or commissions were paid or incurred by the Company.
Nasdaq Compliance and Reverse Stock Split
On August 2, 2024, the Company filed a preliminary proxy statement on Schedule 14A in connection with the Company’s annual meeting of stockholders scheduled for September 26, 2024 (the “September 26, 2024 annual meeting”). On August 6, 2024, the Company filed an amended proxy statement on Schedule PRER14A indicating that in the event the Company does not regain compliance with the Bid Price Rule on or before September 26, 2024, then at the annual meeting, the Company intends to seek the approval of its stockholders to implement a reverse stock split in the range within a range of one-for-five (1-for-5) to a maximum of a one-for-two hundred (1-for-200).
On August 6, 2024, the Company received notice from the Staff indicating that the bid price for the Company’s common stock had closed below $ per share for the 10-consecutive trading day period ended August 5, 2024 and, accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stock Rule”) and its securities were subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”).
On August 12, 2024, the Company timely requested a hearing before the Panel, which request automatically stayed any further action by Nasdaq until the hearing was held and the expiration of any extension period that may have been granted by the Panel. The Company’s common stock continued to trade on Nasdaq under the symbol “VERB” pending completion of the hearing process.
On August 28, 2024, the Panel determined to grant the Company a temporary exception until October 21, 2024, to effect a reverse stock split of its common stock and thereafter regain compliance with The Nasdaq Stock Market LLC’s Listing Rule 5550(a)(2). On October 2, 2024, the Panel amended the exception granted to the Company to provide that the Company has until October 22, 2024, to effect a reverse stock split to regain compliance with Nasdaq Listing Rule 5550(a)(2).
At the September 26, 2024 annual meeting, the Company’s stockholders voted to approve a reverse stock split within a range of one-for-five (1-for-5) to a maximum of a one-for-two hundred (1-for-200). Given the then price of the Company’s shares and the limited time frames established by the Panel, on October 8, 2024 the Board implemented a 1 for 200 reverse stock split (the “Reverse Stock Split”) and on October 9, 2034 the Company’s shares began trading on post-split basis.
On October 23, 2024, after the elapse of ten trading days, the Company received a letter from the Nasdaq Stock Market stating that the Company had regained compliance with the minimum bid price requirement of $ per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2). As is customary, the Company will be subject to a mandatory panel monitor for a period of one year from October 23, 2024. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (the “Staff”) finds the Company is again out of compliance with the minimum bid price requirement, notwithstanding Nasdaq Listing Rule 5810(c)(2), then the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Nasdaq Panel or a newly convened hearing panel if the initial Panel is unavailable.
Corporate Action, Change of Control, and Extraordinary Performance Agreements
As of the date of this Form 10-Q, the Company’s shares have traded and are continuing to trade at a price that results in a market cap that is significantly less than the Company’s current net cash position. Accordingly, the Company’s Board of Directors has determined that the Company is vulnerable to hostile takeover action and that any such action at this time is not in the best interests of its stockholders. The Company does not currently have any poison pill type provisions and due to previous reverse stock splits and other capital markets activities, the Company’s management and board members currently own an insignificant number of shares and as such would be ineffective in voting such shares to thwart any hostile takeover actions. Until such time as the Board determines whether it is necessary or advisable to adopt a poison pill provision or other anti-takeover measure, on October 31, 2024 the Board determined to approve the entry into Corporate Action, Change of Control, and Extraordinary Performance Agreements (the “Agreement”) with Rory J. Cutaia, Founder, Chairman and CEO of the Company, and James Geiskopf, Lead Director, (the “Awardees”) pursuant to which the Company will issue fully vested restricted stock units (“RSU”) subject to certain triggering events (the “Triggering Events”), as described below. Each RSU represents the right to be issued one share of common stock (the shares upon vesting, are subject to the restrictions as set forth in the Agreement, under the Company’s 2019 Omnibus Incentive Plan, or the RSU award agreement).
The Triggering Events include, among other things, the following:
The Triggering Events also include partial issuances of RSU’s to the Awardees through the achievement of extraordinary performance-based quarterly revenue milestones as determined by the Board (the “Revenue Milestones”), and as measured on specific dates, each a “Measurement Date” defined as December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025, and the Awardees providing continuous services through the achievement of such milestones. Pursuant to the Agreement, each Awardee may be entitled to receive between (i) between $500,000 and $900,000 as of December 31, 2024, (ii) between $1.1M and $1.5M as of March 31, 2025, (iii) between $1.7M and $2.1M as of June 30, 2025, (iv) between $2.3M and $2.7M as of September 30, 2025, and (v) $2.9M and $3.3M as of December 31, 2025. The achievement of each of the applicable quarterly Revenue Milestones on each Measurement Date will be reasonably determined by the Company’s Board of Directors. and RSU’s upon achieving the following Revenue Milestones
The foregoing description of the above Agreement is qualified in its entirety by reference to the Agreement, copies of which are attached hereto as Exhibit 10.1 and Exhibit 10.2 and incorporated herein by reference.
|